Ongoing Disclosure Notice- Antony Barclay

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013
To NZX Limited; and
Name of listed issuer:
Rua Bioscience Limited (Rua)
Date this disclosure made:
20-Aug-25
Date of last disclosure:
9-Jun-25
Director or senior manager giving disclosure
Full name(s):
Antony Barclay
Name of listed issuer:
Rua
Name of related body corporate (if applicable):
N/A
Position held in listed issuer:
Director
Summary of acquisition or disposal of relevant interest (excluding specified derivatives)
Class of affected quoted financial products: 
Ordinary shares
Nature of the affected relevant interest(s):
Shareholder
For that relevant interest-
Number held in class before acquisition or disposal:
1,739,376
Number held in class after acquisition or disposal:
2,139,376
Current registered holder(s):
N/A - new issue of shares
Registered holder(s) once transfers are registered:
Antony Barclay
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: 
Warrants
Class of underlying financial products:
Ordinary Shares
Details of affected derivative-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
100,642 warrants. This issue of warrants represents
0.041% of the total ordinary shares and warrants on
issue
(being the percentage should all warrants vest and be
exercised). At $0.015 warrant price is $1509.63
A statement as to whether the derivative is cash settled or physically settled:
No consideration is payable for the warrants. Cash
consideration of $0.015 per share is payable on
exercise of the warrants
Maturity date of the derivative (if any):
14/08/2028
Expiry date of the derivative(if any):
14/08/2028
The price specified in the terms of the derivative (if any):
$0.015 per warrant
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative,-
Parties to the derivative:
Antony Barclay
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates:
Two transactions
1 transaction related to issue of 400,000 shares
1 transaction related to issue of 100,642 warrants

Details of transactions requiring disclosure-
Date of transaction:
15‐Aug‐25
Nature of transaction:
Issue of shares @ $0.03 per share
Issue of warrants @ $0.015 per warrant
Name of any other party or parties to the transaction (if known):Rua Bioscience Limited
The consideration, expressed in New Zealand dollars, paid or received for the
acquisition or disposal. If the consideration was not in cash and cannot be readily by
converted into a cash value, describe the consideration:
$30,000 ‐ $12,000 relating to the issue of ordinary 
shares and $18,000 relating to the debt facility.
Number of financial products to which the transaction related:
400,000 shares
100,642 warrants
If the issuer has a financial products trading policy that prohibits directors or senior
managers from trading during any period without written clearance (a closed period)
include the followin
g details—
Whether relevant interests were acquired or disposed of during a closed period:
Yes
Whether prior written clearance was provided to allow the acquisition or disposal to
proceed during the closed period:
Yes
Date of the prior written clearance (if any):
14/08/2025
Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products:
Ordinary Shares
Nature of relevant interest:Registered Holder
For that relevant interest,-
Number held in class:2,139,376
Current registered holder(s):Antony Barclay
For a derivative relevant interest,-
Type of derivative:
Warrants
Details of derivative,-
The notional value of the derivative (if any) or the notional amount of underlying
financial products (if any):
100,642 warrants. This issue of warrants represents
0.041% of the total ordinary shares and warrants on
issue
(being the percentage should all warrants vest and be
exercised
). At $0.015 warrant price is $1509.63
A statement as to whether the derivative is cash settled or physically settled:
No consideration is payable for the warrants. Cash
consideration of $0.015 per share is payable on
exercise of the warrants
Maturity date of the derivative (if any):
14/08/2028
Expiry date of the derivative (if any):
14/08/2028
The price's specified terms (if any):
$0.015 per warrant
Any other details needed to understand how the amount of the consideration payable
under the derivative or the value of the derivative is affected by the value of the
underlying financial products:
N/A
For that derivative relevant interest,-
Parties to the derivative:
Antony Barclay
If the director or senior manager is not a party to the derivative, the nature of the
relevant interest in the derivative:
N/A
Certification
I, certify that, to the best of my knowledge and belief, the information contained in this
disclosure is correct and that I am duly authorised to make this disclosure by all
persons for whom it is made.
Signature of person authorised to sign on behalf of director or officer:
Date of signature:20/08/2025
Name and title of authorised person:Paul Naske, CEO